Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-11-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the partial release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and the shareholding percentages. There is no financial data, no discussion of financial results, no management commentary, and no mention of a report being attached or published. The content focuses solely on share pledge status and shareholder information. This fits the category of a Regulatory Filing (RNS) as it is a regulatory disclosure about share pledge status and not a financial report or other specific filing type.
2021-11-05 Chinese
天士力关于控股股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the partial release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the remaining pledged shares, and the shareholding structure. There is no financial data, earnings information, or report attached or referenced as being published. The content focuses on share pledge status and shareholder information, which fits the category of shareholding or capital structure updates. This is not a full financial report, earnings release, or management discussion. It is a specific announcement about share pledge changes, which aligns best with the category 'Transaction in Own Shares' (POS), as it involves changes in the status of shares held by the controlling shareholder.
2021-11-01 Chinese
天士力关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and references previous related announcements. The document is short (916 characters) and focuses on the update of share buyback activity, which fits the category of a Transaction in Own Shares (POS) filing. It is not a full financial report or earnings release, nor is it an announcement of a report publication. Therefore, the correct classification is POS.
2021-11-01 Chinese
天士力关于公司2021年三季度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the third quarter of 2021. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment field, product, and region for the period January to September 2021. The document explicitly states it is a disclosure of main operating data for the third quarter and is unaudited. It does not contain full financial statements or comprehensive analysis typical of an Interim/Quarterly Report but rather a summary of key operating metrics for the quarter. The document length is 3391 characters, which is relatively short but contains substantive financial data rather than just a notice or certification. Therefore, it fits best as an Interim / Quarterly Report (IR) because it provides substantive financial data for a period shorter than a full fiscal year (Q3 2021). 9M 2021
2021-10-26 Chinese
天士力2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on accounting changes. The report covers the third quarter of 2021 and includes unaudited financial statements and management assurances about the accuracy of the report. The length of the document is substantial (15,000 characters), and it contains actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-26 Chinese
天士力关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving a drug registration certificate from the national drug regulatory authority. It details the drug's registration, development, market situation, and potential impact on the company. The document is short (1530 characters) and serves as a formal public announcement of a regulatory approval event. It does not contain financial statements, management discussion, or detailed financial data. It is not a report or a detailed presentation but a regulatory announcement about a specific event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-21 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.